Nissay Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-23,929
| Closed | -$1.3M | – | 672 |
|
|
2025
Q3 | $1.3M | Sell |
23,929
-438
| -2% | -$25K | 0.01% | 561 |
|
|
2025
Q2 | $1.34M | Buy |
24,367
+831
| +4% | +$48.9K | 0.01% | 579 |
|
|
2025
Q1 | $1.66M | Buy |
23,536
+283
| +1% | +$19K | 0.01% | 550 |
|
|
2024
Q4 | $1.56M | Buy |
23,253
+334
| +1% | +$22.4K | 0.01% | 576 |
|
|
2024
Q3 | $1.61M | Buy |
22,919
+699
| +3% | +$58.4K | 0.01% | 576 |
|
|
2024
Q2 | $1.83M | Buy |
22,220
+849
| +4% | +$70.7K | 0.01% | 523 |
|
|
2024
Q1 | $1.87M | Buy |
21,371
+428
| +2% | +$38.3K | 0.01% | 524 |
|
|
2023
Q4 | $2.02M | Buy |
20,943
+729
| +4% | +$64.5K | 0.02% | 461 |
|
|
2023
Q3 | $1.79M | Buy |
20,214
+710
| +4% | +$63.2K | 0.02% | 468 |
|
|
2023
Q2 | $1.69M | Sell |
19,504
-308
| -2% | -$29K | 0.01% | 487 |
|
|
2023
Q1 | $1.93M | Sell |
19,812
-722
| -4% | -$74.8K | 0.02% | 442 |
|
|
2022
Q4 | $2.13M | Sell |
20,534
-46
| -0.2% | -$4.32K | 0.02% | 420 |
|
|
2022
Q3 | $1.75M | Buy |
20,580
+911
| +5% | +$81.1K | 0.02% | 448 |
|
|
2022
Q2 | $1.63M | Sell |
19,669
-55
| -0.3% | -$4.38K | 0.02% | 463 |
|
|
2022
Q1 | $1.52M | Buy |
19,724
+476
| +2% | +$39.8K | 0.01% | 535 |
|
|
2021
Q4 | $1.7M | Buy |
19,248
+582
| +3% | +$48K | 0.01% | 522 |
|
|
2021
Q3 | $1.44M | Buy |
18,666
+840
| +5% | +$66.3K | 0.01% | 533 |
|
|
2021
Q2 | $1.49M | Buy |
17,826
+334
| +2% | +$26.5K | 0.01% | 533 |
|
|
2021
Q1 | $1.32M | Sell |
17,492
-56,945
| -77% | -$4.65M | 0.01% | 545 |
|
|
2020
Q4 | $6.53M | Sell |
74,437
-12,855
| -15% | -$1.02M | 0.1% | 169 |
|
|
2020
Q3 | $6.64M | Buy |
87,292
+11,381
| +15% | +$1.15M | 0.11% | 150 |
|
|
2020
Q2 | $9.36M | Buy |
75,911
+17,557
| +30% | +$1.74M | 0.18% | 117 |
|
|
2020
Q1 | $4.93M | Buy |
58,354
+43,537
| +294% | +$3.75M | 0.13% | 172 |
|
|
2019
Q4 | $1.25M | Buy |
14,817
+447
| +3% | +$33.8K | 0.03% | 460 |
|
|
2019
Q3 | $969K | Buy |
14,370
+748
| +5% | +$57.6K | 0.02% | 506 |
|
|
2019
Q2 | $1.17M | Sell |
13,622
-336
| -2% | -$28.7K | 0.03% | 450 |
|
|
2019
Q1 | $1.24M | Buy |
13,958
+827
| +6% | +$76.6K | 0.03% | 438 |
|
|
2018
Q4 | $1.12M | Buy |
13,131
+589
| +5% | +$56K | 0.03% | 409 |
|
|
2018
Q3 | $1.22M | Buy |
12,542
+464
| +4% | +$46.3K | 0.03% | 418 |
|
|
2018
Q2 | $1.14M | Buy |
12,078
+556
| +5% | +$48.7K | 0.03% | 416 |
|
|
2018
Q1 | $934K | Buy |
11,522
+171
| +2% | +$14.7K | 0.03% | 450 |
|
|
2017
Q4 | $1.01M | Buy |
+11,351
| New | +$987K | 0.03% | 421 |
|
Other funds holding BMRN
Nissay Asset Management's BMRN Position: Q4 2025 in Review
Nissay Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 23,929 shares — an estimated $1.3M sold.
Nissay Asset Management first reported a position in BMRN in Q4 2017 and held it in 32 quarters. The position peaked at $9.36M in Q2 2020. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Nissay Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Nissay Asset Management sold 23,929 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.3M.
- Nissay Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 32 quarters.
- Nissay Asset Management's BioMarin Pharmaceuticals position peaked at $9.36M in Q2 2020.
- 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Nissay Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.